Howard S. Hochster, MD of Yale Cancer Center discusses the outcomes of the randomized phase 2 study in BRAF-mutated patients with colorectal cancer at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Advertisement
Advertisement
Advertisement